top of page
Research and Development
Sensible Biotherapeutics Research & Development Pipeline
Sensible Biotherapeutics, LLC is in development of a wide array of pharmaceutical and biomedical innovations, ranging from COVID-19 treatments to oncology research. Our primary prospective drug candidate, SBT-0803, is an antisense oligonucleotide designed to potentially halt replication of the SARS-CoV-2 virus.
This page serves as a resource for some of our other initiatives currently in development, including our radiopharmaceutical innovations and our oncology research.
​
​
​
​
​
​
​
​
​
To read about our COVID-19 research, please click here.
bottom of page